



IAP7 Rec'd PCT/PTO 27 FEB 2006

PCT

Docket No.: N0008.0001
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Tadatake Oku et al.

Confirmation No.: 1795

Application No.: 10/507,156

Group Art Unit: Not Yet Assigned

Filed: September 7, 2004

Examiner: Not Yet Assigned

For: NOVEL HEME PEPTIDE

New York, NY

February 27, 2006

FIRST PRELIMINARY AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

Prior to examination on the merits, please amend the above-identified U.S. patent application as follows:

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 6 of this paper.

Remarks begin on page 13 of this paper.

CIVIL 11 1 00

FEE CALCULATION

Any additional fee required has been calculated as follows:

___ If checked, "Small Entity" status is claimed.

	Claims Remaining After	Highest Number Previously Paid	Number Extra Claims Present	Rate	Additional Fee
Total	22	- 22* =	0	x	0.00
Independent	1	- 3** =	0	x	0.00
First presentation of Multiple Dependent Claim(s) (if applicable)					0.00
TOTAL					0.00

*not less than 20

** not less than 3

No additional fee is required.

In the event a fee is required or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 50-2215.

CONTINGENT EXTENSION REQUEST

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 CFR 1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 CFR 1.135. The fee under 37 CFR 1.17 should be charged to our Deposit Account No. 50-2215.